辅助化疗未给非典型类癌患者带来生存优势
该研究基于美国国家癌症数据库2006至2011年数据,纳入581例接受肺叶或全肺切除的非典型类癌患者,采用倾向性评分和生存分析评估辅助化疗与pN+及pN0患者的生存关联。结果显示,pN+和pN0患者接受辅助化疗均未获得生存优势,需进一步研究明确化疗的合理使用。
要点
- pN+非典型类癌患者辅助化疗未显示生存获益(p=0.46)。
- pN0患者辅助化疗亦无生存优势(p=0.54)。
- 需进一步研究明确非典型类癌术后化疗的适用人群。
核心结论
- 在国家级分析中,pN+和pN0非典型类癌患者术后辅助化疗均未带来生存优势。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库2006至2011年数据,纳入581例接受肺叶或全肺切除的成人非典型类癌患者,采用4:1最近邻倾向性评分和生存分析。
主要发现
- 581例中363例(62.5%)为pN0,218例(37.5%)为pN+。
- pN0患者中15例(4.1%)接受辅助化疗,pN+患者中89例(40.8%)接受辅助化疗。
- pN+患者未调整12个月和60个月生存率:辅助化疗组98.9%和47.9%,单纯手术组98.4%和67.1%,p=0.46。
- 倾向性匹配后pN0患者12个月和60个月生存率:辅助化疗组86.7%和73.3%,单纯手术组87.9%和72.3%,p=0.54。
临床怎么用
- 对于pN+或pN0非典型类癌患者,术后辅助化疗不应常规推荐以追求生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the use of adjuvant chemotherapy in patients with pathologically node-positive (pN+) atypical carcinoid tumor of the lung is an accepted practice, controversy exists about its use in pathologically node-negative (pN0) patients. Our aim was to determine whether a survival advantage exists in patients receiving chemotherapy postoperatively for pN0 or pN+ atypical carcinoid tumors of the lung. METHODS: Adult patients treated with lobectomy or pneumonectomy for pulmonary atypical carcinoid tumor were identified using the National Cancer Data Base, 2006 to 2011. Propensity scoring (4:1 nearest neighbor algorithm) and survival analysis were used to examine the association between adjuvant chemotherapy and pN+ versus pN0 atypical carcinoid tumors. RESULTS: Of the total 581 patients identified with a diagnosis of atypical carcinoid of the lung, 363 (62.5%) were found to be node negative at the time of operation and 218 (37.5%) had node-positive disease. Adjuvant chemotherapy was used in 15 patients (4.1%) with pN0 disease and 89 patients (40.8%) with pN+ disease. Unadjusted survival, at 12 and 60 months, was similar between pN+ patients who were treated with adjuvant chemotherapy versus patients who received operation alone (adjuvant chemotherapy: 98.9% at 12 months and 47.9% at 60 months versus operation alone: 98.4% and 12 months and 67.1% at 60 months, p = 0.46) and for propensity-matched pN0 (adjuvant chemotherapy: 86.7% at 12 months and 73.3% at 60 months versus operation alone: 87.9% at 12 months and 72.3% at 60 months, p = 0.54). CONCLUSIONS: In a national-level analysis, the use of adjuvant chemotherapy postoperatively in patients with pN+ and pN0 disease conferred no survival advantage; further study is needed to determine proper chemotherapy use for these patients.
引用
- Anderson KL, Mulvihill MS, Speicher PJ, et al. Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann Thorac Surg. 2017. PMID: 28760471. doi:10.1016/j.athoracsur.2017.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。